This study investigates the potential clinical synergy between the poly(adenosine 5'-diphosphate [ADP]-ribose) polymerase (PARP) inhibitor niraparib (Zejula®) and concomitant statins, exploring their combined effects on progression-free survival (PFS) in ovarian cancer patients. We retrospectively analysed niraparib registrational clinical trials in ovarian cancer to investigate potential interactions between niraparib and statins. In the PRIMA trial, patients receiving niraparib …